Literature DB >> 20046270

Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.

.   

Abstract

This statement is intended for health care professionals caring for neonates and young infants. The objectives of this statement are to review the short and long term effects of systemic and inhaled postnatal corticosteroids for the prevention or treatment of evolving or established chronic lung disease, and to make recommendations for the use of corticosteroids in infants with very low birth weight. The routine use of systemic dexamethasone for the prevention or treatment of chronic lung disease in infants with very low birth weight is not recommended.

Entities:  

Keywords:  Chronic lung disease; Corticosteroids; Infant; Newborn; Preterm; Very low birth weight

Year:  2002        PMID: 20046270      PMCID: PMC2794525          DOI: 10.1093/pch/7.1.20

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  41 in total

1.  Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function.

Authors:  L Doyle; P Davis
Journal:  J Paediatr Child Health       Date:  2000-04       Impact factor: 1.954

Review 2.  Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants.

Authors:  H L Halliday; R A Ehrenkranz
Journal:  Cochrane Database Syst Rev       Date:  2001

3.  Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease.

Authors:  T Bhuta; A Ohlsson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

4.  Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease.

Authors:  B P Murphy; T E Inder; P S Huppi; S Warfield; G P Zientara; R Kikinis; F A Jolesz; J J Volpe
Journal:  Pediatrics       Date:  2001-02       Impact factor: 7.124

5.  Early dexamethasone therapy in preterm infants: a follow-up study.

Authors:  T F Yeh; Y J Lin; C C Huang; Y J Chen; C H Lin; H C Lin; W S Hsieh; Y J Lien
Journal:  Pediatrics       Date:  1998-05       Impact factor: 7.124

Review 6.  Inhaled steroids for neonatal chronic lung disease.

Authors:  P Lister; R Iles; B Shaw; F Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 7.  Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.

Authors:  V Shah; A Ohlsson; H L Halliday; M S Dunn
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  Early postnatal dexamethasone treatment and increased incidence of cerebral palsy.

Authors:  E S Shinwell; M Karplus; D Reich; Z Weintraub; S Blazer; D Bader; S Yurman; T Dolfin; A Kogan; S Dollberg; E Arbel; M Goldberg; I Gur; N Naor; L Sirota; S Mogilner; A Zaritsky; M Barak; E Gottfried
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-11       Impact factor: 5.747

9.  Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant.

Authors:  B S Brozanski; J G Jones; C H Gilmour; M J Balsan; R L Vazquez; B A Israel; B Newman; F B Mimouni; R D Guthrie
Journal:  J Pediatr       Date:  1995-05       Impact factor: 4.406

10.  The effect of dexamethasone on time averaged mean velocity in the middle cerebral artery in very low birth weight infants.

Authors:  A Ohlsson; J Bottu; J Govan; M L Ryan; T Myhr; K Fong
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

View more
  3 in total

Review 1.  Evidence for adverse effect of perinatal glucocorticoid use on the developing brain.

Authors:  Young Pyo Chang
Journal:  Korean J Pediatr       Date:  2014-03-31

2.  Effect of dexamethasone on intelligence and hearing in preterm infants: a meta-analysis.

Authors:  Ruolin Zhang; Tao Bo; Li Shen; Senlin Luo; Jian Li
Journal:  Neural Regen Res       Date:  2014-03-15       Impact factor: 5.135

Review 3.  Phenotypes of Bronchopulmonary Dysplasia.

Authors:  Shih-Hsin Wang; Po-Nien Tsao
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.